US Stock Movements: Trevi Therapeutics surges on October 20 due to CORAL data and chronic cough medication
Bitget异动解读2026/10/20 19:41Trevi Therapeutics October 20th Surge Interpretation
Keywords: CORAL data, chronic cough medication
1. On October 20th, Trevi delivered an oral presentation on CORAL phase IIb patient-reported outcomes at the CHEST 2026 conference; according to related materials, patient-reported outcomes in IPF-related chronic cough showed early and sustained improvement during the trial.
2. According to a report on October 20th, Morgan Stanley recently initiated coverage of eight biotechnology companies for the first time and mentioned Trevi’s market opportunity in the chronic cough field; the company is developing the oral extended-release nalfurafine, Haduvio, for various types of chronic cough.
(Disclaimer: This content is generated by AI technology gathering and summarizing publicly available information, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Claude’s usage in Microsoft 365 is less than one tenth of Copilot’s.



Nvidia DDGX B200 system will connect to the IBM Quantum Nighthawk quantum computer
